Diversity of malignancies in patients with different types of inborn errors of immunity
Abstract Genetic defects in the development, maturation, and/or function of the immune cells can lead to Inborn errors of immunity (IEI) which may predispose patients to malignancies. The overall risk for cancer in children with IEI ranges from 4 to 25% and the type of malignancy is highly dependent on the specific mutant gene underlying IEI. We investigated 3056 IEI patients registered in the Iranian national registry between the years 1999 and 2020 in this retrospective cohort study. The frequency of malignancy and its association with the type of IEI in these patients were evaluated. A total of 82 IEI patients with malignancy were enrolled in this study. Among them, predominantly lymphoma was the most common type of malignancy (67.1%), followed by leukemia (11%), and cancers of the head and neck (7.3%). Among identified lymphoma cancers, non-Hodgkin’s lymphomas were the most frequent type (43.9%) followed by different subtypes of Hodgkin’s lymphoma (23.2%). Solid tumors (18.3%) appeared to be very heterogeneous by type and localization. The correlation between the type of malignancy and survival status and the association between the type of malignancy and IEI entities were unremarkable. The awareness of the association between the presence of IEI and cancer highlights the importance of a synergistic effort by oncologists and immunologists in the early diagnosis of malignancy and personalized therapeutic strategies in IEI patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Allergy, asthma and clinical immunology - 18(2022), 1 vom: 12. Dez. |
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Hematologic cancers |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1186/s13223-022-00747-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2133062572 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2133062572 | ||
| 003 | DE-627 | ||
| 005 | 20240324001741.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230506s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13223-022-00747-2 |2 doi | |
| 035 | |a (DE-627)OLC2133062572 | ||
| 035 | |a (DE-He213)s13223-022-00747-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Tavakol, Marzieh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diversity of malignancies in patients with different types of inborn errors of immunity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Abstract Genetic defects in the development, maturation, and/or function of the immune cells can lead to Inborn errors of immunity (IEI) which may predispose patients to malignancies. The overall risk for cancer in children with IEI ranges from 4 to 25% and the type of malignancy is highly dependent on the specific mutant gene underlying IEI. We investigated 3056 IEI patients registered in the Iranian national registry between the years 1999 and 2020 in this retrospective cohort study. The frequency of malignancy and its association with the type of IEI in these patients were evaluated. A total of 82 IEI patients with malignancy were enrolled in this study. Among them, predominantly lymphoma was the most common type of malignancy (67.1%), followed by leukemia (11%), and cancers of the head and neck (7.3%). Among identified lymphoma cancers, non-Hodgkin’s lymphomas were the most frequent type (43.9%) followed by different subtypes of Hodgkin’s lymphoma (23.2%). Solid tumors (18.3%) appeared to be very heterogeneous by type and localization. The correlation between the type of malignancy and survival status and the association between the type of malignancy and IEI entities were unremarkable. The awareness of the association between the presence of IEI and cancer highlights the importance of a synergistic effort by oncologists and immunologists in the early diagnosis of malignancy and personalized therapeutic strategies in IEI patients. | ||
| 650 | 4 | |a Primary immunodeficiency | |
| 650 | 4 | |a Inborn errors of immunity | |
| 650 | 4 | |a Malignancy | |
| 650 | 4 | |a Hematologic cancers | |
| 650 | 4 | |a Lymphoma | |
| 650 | 4 | |a Leukemia | |
| 650 | 4 | |a Solid tumors | |
| 700 | 1 | |a Delavari, Samaneh |4 aut | |
| 700 | 1 | |a Salami, Fereshte |4 aut | |
| 700 | 1 | |a Ansari, Sarina |4 aut | |
| 700 | 1 | |a Rasouli, Seyed Erfan |4 aut | |
| 700 | 1 | |a Chavoshzadeh, Zahra |4 aut | |
| 700 | 1 | |a Sherkat, Roya |4 aut | |
| 700 | 1 | |a Ahanchian, Hamid |4 aut | |
| 700 | 1 | |a Aleyasin, Soheila |4 aut | |
| 700 | 1 | |a Esmaeilzadeh, Hossein |4 aut | |
| 700 | 1 | |a Moazzen, Nasrin |4 aut | |
| 700 | 1 | |a Shafiei, Alireza |4 aut | |
| 700 | 1 | |a Abolnezhadian, Farhad |4 aut | |
| 700 | 1 | |a Iranparast, Sara |4 aut | |
| 700 | 1 | |a Ebrahimi, Sareh sadat |4 aut | |
| 700 | 1 | |a Moeini Shad, Tannaz |4 aut | |
| 700 | 1 | |a Pashangzadeh, Salar |4 aut | |
| 700 | 1 | |a Nazari, Farzad |4 aut | |
| 700 | 1 | |a Rezaei, Arezou |4 aut | |
| 700 | 1 | |a Saeedi-Boroujeni, Ali |4 aut | |
| 700 | 1 | |a Nabavi, Mohammad |4 aut | |
| 700 | 1 | |a Arshi, Saba |4 aut | |
| 700 | 1 | |a Fallahpour, Morteza |4 aut | |
| 700 | 1 | |a Bemanian, Mohammad hassan |4 aut | |
| 700 | 1 | |a Sharafian, Samin |4 aut | |
| 700 | 1 | |a Shokri, Sima |4 aut | |
| 700 | 1 | |a Eshaghi, Sarvin |4 aut | |
| 700 | 1 | |a Nazari, Shiva |4 aut | |
| 700 | 1 | |a Shamsian, Bibi Shahin |4 aut | |
| 700 | 1 | |a Dargahi Mal-Amir, Mehrdad |4 aut | |
| 700 | 1 | |a Khazaei, Roya |4 aut | |
| 700 | 1 | |a Ashkevari, Pooya |4 aut | |
| 700 | 1 | |a Khavandegar, Armin |4 aut | |
| 700 | 1 | |a Haghi, Sabahat |4 aut | |
| 700 | 1 | |a Esmaeili, Marzie |4 aut | |
| 700 | 1 | |a Abolhassani, Hassan |4 aut | |
| 700 | 1 | |a Rezaei, Nima |0 (orcid)0000-0002-3836-1827 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Allergy, asthma and clinical immunology |d BioMed Central, 2005 |g 18(2022), 1 vom: 12. Dez. |h Online-Ressource |w (DE-627)512662487 |w (DE-600)2236671-4 |w (DE-576)321851072 |x 1710-1492 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:1 |g day:12 |g month:12 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13223-022-00747-2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 1 |b 12 |c 12 | ||